Truveta

💡 PCOS has a new name: Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The change reflects a growing understanding that this condition is not just about ovarian cysts, but a complex hormonal and metabolic condition that can affect weight, insulin resistance, reproductive health, skin, and mental health. We examined GLP-1 prescribing among women with PCOS and found that prescriptions for semaglutide or tirzepatide increased from 2.4% in 2021 to 17.6% in 2025: over a 7-fold increase 📈 As PCOS becomes PMOS, understanding the metabolic dimensions of the condition is so important, and how real-world evidence can help track changing care patterns over time. 🔗 Learn more: https://tr.vet/4tR8ASy

That’s a wrap on #ISPORAnnual! Thank you to everyone who stopped by our booth and spent some time with us and the dogs from the Alliance of Therapy Dogs 🐶 And most of all, thank you to our on-site team for making it all happen. Safe travels back home! See you next year 👋 ISPOR—The Professional Society for Health Economics and Outcomes Research

🫀 Most patients with newly identified heart failure are not receiving the recommended follow-up heart function assessment, despite clinical guidelines calling for reassessment and treatment optimization. A new study from Truveta Research and collaborators at Yale School of Medicine, Yale New Haven Hospital, and Duke University School of Medicine published in JAMA Network Open analyzed data from more than 340,000 adults with newly documented heart failure with reduced ejection fraction (HFrEF). One key finding: only 33.8% of patients received repeat echocardiography within one year of diagnosis, even though follow-up assessment is critical for guiding long-term care and treatment decisions. 🔗 Learn more: https://tr.vet/4dIiHDr

✅ Another day of ISPOR, another day of insights and connection! Take a look at our poster presenters in action and of course, some furry friends at the Truveta booth. Huge thank you to our poster presenters Youngwon Kim, Karen Gilbert Farrar, PhD, and Ehsan Alipour, MD, PhD 👏 ISPOR—The Professional Society for Health Economics and Outcomes Research

Yesterday was a busy day at #ISPOR2026! Some highlights: 1️⃣ SVP of Product Michael Simonov shared how AI and RWD can shorten evidence timelines, delivering insights in minutes, not months in his theater presentation. 2️⃣ Senior Research Analyst Karen Gilbert Farrar, PhD and ML Postdoc Researcher Youngwon Kim presented research posters, one on gestational weight changes and the effect on newborn weight (https://tr.vet/49D9Xgs), and another on mapping oncology patient journeys (https://tr.vet/4nIO8SG). 3️⃣ We had a special guest at the booth, showing attendees the art of the paw-sible: Cooper from the Alliance of Therapy Dogs 🐾 Stay tuned for more ISPOR updates! ISPOR—The Professional Society for Health Economics and Outcomes Research

Last night, we kicked off #ISPOR2026 in Philadelphia with leaders across life sciences and healthcare for an evening focused on connecting ideas, data, and people. Thank you to everyone who joined us and helped make the event such a success 👏 It was an energizing start to the week with great conversations around real-world evidence, HEOR, and the future of data-driven healthcare decision-making. Attending ISPOR? Don’t forget to stop by our booth (#505) to say hello 👋 We’d love to connect and share how Truveta can help advance evidence generation at scale. ISPOR—The Professional Society for Health Economics and Outcomes Research

Clinical AI is accelerating access to medical evidence in powerful ways. But clinicians also need answers grounded in the experiences of patients who resemble the ones sitting in front of them. In this piece, Truveta President and Chief Scientific Officer Johnathan M. Lancaster, MD PhD explores why the future of clinical decision support will combine published literature with real-world data—bringing together published literature and real-time insights from Truveta Intelligence to help clinicians get faster, more contextual answers at the point of care.

Our fourth annual symposium brought together leaders across healthcare for a packed week of discussion, collaboration, and connection in Seattle 📍 From mainstage discussions to hands-on demos and candid conversations, the focus was on how we move faster from data to evidence and from insight to impact for patients. Check out this recap from Truveta Symposium 2026 ⬇️

At Truveta Symposium 2026, we unveiled Truveta Intelligence: a new, AI-powered experience that delivers real-time insights from continuously refreshed, real-world data in minutes, not months. We sat down with team members from across the organization to ask them about how Intelligence can help shorten timelines between question and answer. With each answer, you get data-backed intelligence built on the 130 million patient records in Truveta Data. Learn more: https://tr.vet/435Ihgv

⏰ Just a few days left until #ISPOR2026 kicks off, and we're excited to share the research from our engineering team that we'll be presenting at the event. From zero-shot lung cancer risk prediction to modeling oncology patient journeys and advancing approaches for cancer screening and data completeness, we can't wait to share the findings next week. 🔗 Learn more about Truveta's ISPOR activities: https://tr.vet/4n9ONfG ISPOR—The Professional Society for Health Economics and Outcomes Research